Is VISION BLURRED a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed VISION BLURRED.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 27 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported VISION BLURRED to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and VISION BLURRED. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause VISION BLURRED, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes VISION BLURRED. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if VISION BLURRED ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing VISION BLURRED: 27
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where VISION BLURRED is a reported side effect: 0.8111%

FDA reports of any drug causing VISION BLURRED : 38849
Average percentage for all medicated patients where VISION BLURRED is reported as a complication: 0.2435%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with VISION BLURRED:

LYRICA (3909 patients)
ASPIRIN (2707 patients)
SEROQUEL (2416 patients)
VIOXX (1776 patients)
FOSAMAX (1751 patients)
NEURONTIN (1682 patients)
LISINOPRIL (1332 patients)
LIPITOR (1298 patients)
SYNTHROID (1274 patients)
TYSABRI (1248 patients)
CYMBALTA (1164 patients)
PREDNISONE (1118 patients)
ZOMETA (1102 patients)
HUMIRA (1096 patients)
NEXIUM (1088 patients)
SPIRIVA (1072 patients)
XANAX (1057 patients)
AVONEX (1025 patients)
LASIX (951 patients)
ZOLOFT (926 patients)
REMICADE (917 patients)
ATENOLOL (897 patients)
ENBREL (895 patients)
ZYPREXA (863 patients)
COUMADIN (834 patients)
AMBIEN (826 patients)
ALBUTEROL (817 patients)
OMEPRAZOLE (812 patients)
HYDROCHLOROTHIAZIDE (801 patients)
IBUPROFEN (795 patients)
LANTUS (790 patients)
SIMVASTATIN (778 patients)
AREDIA (777 patients)
CHANTIX (774 patients)
TOPROL-XL (770 patients)
PAXIL (756 patients)
PLAVIX (754 patients)
CELEBREX (753 patients)
GABAPENTIN (752 patients)
HEPARIN SODIUM INJECTION (735 patients)
METFORMIN HCL (720 patients)
ADVAIR DISKUS 100/50 (709 patients)
ZOCOR (704 patients)
NORVASC (703 patients)
PROTONIX (700 patients)
PREVACID (697 patients)
PRILOSEC (695 patients)
LEXAPRO (692 patients)
CLONAZEPAM (675 patients)
KLONOPIN (673 patients)
OXYCONTIN (668 patients)
FUROSEMIDE (668 patients)
FOLIC ACID (667 patients)
ACETAMINOPHEN (662 patients)
VICODIN (648 patients)
VITAMIN D (648 patients)
TOPAMAX (645 patients)
ACCUTANE (643 patients)
CRESTOR (641 patients)
GILENYA (638 patients)
DIGOXIN (629 patients)
KETEK (625 patients)
LEVOTHYROXINE SODIUM (624 patients)
METHOTREXATE (619 patients)
ATIVAN (593 patients)
LORAZEPAM (593 patients)
BYETTA (588 patients)
LAMICTAL (588 patients)
PROZAC (580 patients)
WELLBUTRIN (561 patients)
AVANDIA (544 patients)
VIAGRA (541 patients)
PERCOCET (540 patients)
XALATAN (534 patients)
DIOVAN (531 patients)
FORTEO (529 patients)
MULTI-VITAMINS (513 patients)
VALIUM (508 patients)
CIALIS (506 patients)
PREMARIN (502 patients)
ABILIFY (490 patients)
CALCIUM (488 patients)
POTASSIUM CHLORIDE (481 patients)
HUMALOG (476 patients)
DIAZEPAM (475 patients)
TRAZODONE HCL (463 patients)
RESTASIS (455 patients)
COREG (449 patients)
INSULIN (448 patients)
FLOMAX (443 patients)
LEVAQUIN (442 patients)
EFFEXOR (439 patients)
PREDNISONE TAB (437 patients)
ALPRAZOLAM (428 patients)
SINGULAIR (426 patients)
REBIF (425 patients)
WARFARIN SODIUM (425 patients)
MULTI-VITAMIN (410 patients)
CELEXA (401 patients)
RISPERDAL (401 patients)
EXJADE (397 patients)
VESICARE (397 patients)
EFFEXOR XR (396 patients)
ALLOPURINOL (396 patients)
ZOFRAN (395 patients)
AMLODIPINE (394 patients)
LORTAB (391 patients)
DURAGESIC-100 (389 patients)
GLUCOPHAGE (388 patients)
PEGASYS (382 patients)
ZYRTEC (382 patients)
DEXAMETHASONE (381 patients)
OXYCODONE HCL (380 patients)
FLEXERIL (376 patients)
AMOXICILLIN (363 patients)
ALLEGRA (362 patients)
DEPAKOTE (358 patients)
BACLOFEN (354 patients)
RANITIDINE (354 patients)
BENADRYL (353 patients)
TRAMADOL HCL (348 patients)
DECADRON (347 patients)
GLYBURIDE (346 patients)
RIBAVIRIN (346 patients)
METOPROLOL TARTRATE (344 patients)
FISH OIL (335 patients)
PRISTIQ (335 patients)
BOTOX COSMETIC (332 patients)
ACTOS (332 patients)
CLONIDINE (327 patients)
PREDNISOLONE (324 patients)
METFORMIN (320 patients)
AMITRIPTYLINE HCL (318 patients)
PAROXETINE HCL (317 patients)
COZAAR (313 patients)
CITALOPRAM HYDROBROMIDE (311 patients)
MORPHINE (309 patients)
ZANTAC (309 patients)
TEGRETOL (308 patients)
SANDOSTATIN LAR (306 patients)
VITAMIN E (304 patients)
NITROGLYCERIN (295 patients)
ZETIA (294 patients)
NAPROXEN (285 patients)
ZITHROMAX (285 patients)
ALL OTHER THERAPEUTIC PRODUCTS (284 patients)
FLONASE (283 patients)
VITAMINS (283 patients)
THALIDOMIDE (282 patients)
GLIPIZIDE (281 patients)
VITAMIN B-12 (278 patients)
REVLIMID (274 patients)
GEODON (273 patients)
ASCORBIC ACID (271 patients)
METOPROLOL (270 patients)
TYLENOL (264 patients)
ACIPHEX (262 patients)
SOMA (260 patients)
FLUOXETINE (257 patients)
BOTOX (251 patients)
ACTONEL (250 patients)
TEMAZEPAM (248 patients)
ELAVIL (245 patients)
REGLAN (243 patients)
DILAUDID (243 patients)
AVELOX (240 patients)
NIASPAN (239 patients)
DILANTIN (238 patients)
TYLENOL (CAPLET) (237 patients)
MOTRIN (236 patients)
LEVOXYL (236 patients)
AUGMENTIN '125' (236 patients)
HYDROCODONE BITARTRATE (236 patients)
ULTRAM (236 patients)
FENTANYL (233 patients)
AMARYL (229 patients)
COLACE (226 patients)
RAMIPRIL (226 patients)
COMBIVENT (225 patients)
CEPHALEXIN (224 patients)
SPIRONOLACTONE (224 patients)
ACYCLOVIR (223 patients)
PROVIGIL (223 patients)
CLARITIN (223 patients)
LUCENTIS (223 patients)
FLUCONAZOLE (222 patients)
LAMOTRIGINE (221 patients)
IRON (219 patients)
SYMBICORT (219 patients)
BENICAR (218 patients)
KEPPRA (217 patients)
PROMETHAZINE (216 patients)
PROPRANOLOL (215 patients)
ARANESP (215 patients)
LEVITRA (214 patients)
PEPCID (214 patients)
LOVASTATIN (214 patients)
CIPROFLOXACIN (213 patients)
HYDROCODONE (213 patients)
LOPRESSOR (213 patients)
MIRTAZAPINE (212 patients)
TRILEPTAL (211 patients)
VERAPAMIL (211 patients)
ARIMIDEX (209 patients)
CLINDAMYCIN (209 patients)
BETASERON (209 patients)
VELCADE (209 patients)
PEG-INTRON (209 patients)
METOPROLOL SUCCINATE (208 patients)
YASMIN (206 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about VISION BLURRED and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.